Treatment of inoperable large cell neuroendocrine lung cancer with single agent temozolomide

Annika Marie Ørting; Malene Martini Clausen; Patrick Soldath; Rene H Petersen; Ulrich Knigge; Mikkel Andreassen; Andreas Kjær; Seppo W Langer

doi:10.1080/0284186X.2023.2258444

Treatment of inoperable large cell neuroendocrine lung cancer with single agent temozolomide

Acta Oncol. 2023 Dec;62(12):1952-1955. doi: 10.1080/0284186X.2023.2258444. Epub 2023 Sep 15.

Authors

Annika Marie Ørting¹, Malene Martini Clausen^{1

2

3}, Patrick Soldath^{2

4

5}, Rene H Petersen^{2

4

5}, Ulrich Knigge^{2

6

7}, Mikkel Andreassen^{2

4

7}, Andreas Kjær^{2

3

8}, Seppo W Langer^{1

2

4}

Affiliations

¹ Department of Oncology, Copenhagen University Hospital - Rigshospitalet, Kobenhavn, Denmark.
² ENETS European Neuroendocrine Tumor Center of Excellence, Rigshospitalet, Denmark.
³ Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging, Copenhagen University Hospital - Rigshospitalet, Rigshospitalet, Denmark.
⁴ Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
⁵ Department of Cardiothoracic Surgery, Copenhagen University Hospital - Rigshospitalet, Rigshospitalet, Denmark.
⁶ Department of Gastrointestinal Surgery, Copenhagen University Hospital - Rigshospitalet, Rigshospitalet, Denmark.
⁷ Department of Endocrinology, Copenhagen University Hospital - Rigshospitalet, Rigshospitalet, Denmark.
⁸ Department of Biomedical Science, University of Copenhagen, Copenhagen, Denmark.

PMID: 37713358
DOI: 10.1080/0284186X.2023.2258444

No abstract available

MeSH terms

Carcinoma, Large Cell*
Carcinoma, Neuroendocrine*
Dacarbazine / therapeutic use
Humans
Lung Neoplasms* / drug therapy
Neuroendocrine Tumors*
Temozolomide / therapeutic use
Treatment Outcome

Substances

Temozolomide
Dacarbazine